REGENERON PHARMACEUTICALS (REGN)

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 11,851 full-time employees. The firm's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. The company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through research initiatives, such as Regeneron Genetics Center. The company operates gene therapy programs targeting different forms of congenital, monogenic hearing loss. Its advanced clinical-stage candidate is DB-OTO, which is an investigational cell-selective, adeno-associated virus (AAV) gene therapy.

Company Info

REGENERON PHARMACEUTICALS

777 Old Saw Mill River Road

Tarrytown NEW YORK 10591

P: 17813705000

CEO: Leonard S. Schleifer

Employees: 11851

Website: https://www.regeneron.com/